Akebia Therapeutics - Public Comps and Valuation Multiples

Akebia Therapeutics Overview

About Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Founded

2007

HQ

Employees

181

Website

akebia.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $240M

Last FY EBITDA -$13.7M

EV

$313M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Akebia Therapeutics Financials

As of December 2025, Akebia Therapeutics reported last 12-month revenue of $240M.

In the same period, Akebia Therapeutics generated $204M in LTM gross profit and $12.3M in net income.

See Akebia Therapeutics valuation multiples based on analyst estimates

Akebia Therapeutics P&L

In the most recent fiscal year, Akebia Therapeutics reported revenue of $160M and EBITDA of -$13.7M.

Akebia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Akebia Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$240M	XXX	$160M	XXX	XXX	XXX
Gross Profit	$204M	XXX	$97.0M	XXX	XXX	XXX
Gross Margin	85%	XXX	61%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$13.7M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-9%	XXX	XXX	XXX
EBIT	$40.3M	XXX	-$50.4M	XXX	XXX	XXX
EBIT Margin	17%	XXX	-31%	XXX	XXX	XXX
Net Profit	$12.3M	XXX	-$69.4M	XXX	XXX	XXX
Net Margin	5%	XXX	-43%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Akebia Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $240M. In the most recent fiscal year, Akebia Therapeutics achieved $160M in revenue and -$13.7M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$240M	Analyst estimates available to subscribers	$160M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$204M	Analyst estimates available to subscribers	$97.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	84.9% gross margin	Analyst estimates available to subscribers	60.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$13.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-8.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$40.3M	Analyst estimates available to subscribers	-$50.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.8% EBIT margin	Analyst estimates available to subscribers	-31.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$12.3M	Analyst estimates available to subscribers	-$69.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	5.2% net profit margin	Analyst estimates available to subscribers	-43.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Akebia Therapeutics

This financial data table provides comprehensive performance metrics for Akebia Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Akebia Therapeutics generated $240M in revenue over the last twelve months.
Gross profit for the last twelve months was $204M.
Net income over the last twelve months reached $12.3M.

Fiscal Year Performance

In the most recent fiscal year, Akebia Therapeutics reported $160M in total revenue.
Fiscal year EBITDA was -$13.7M.
The company maintained a gross profit margin of 60.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was -8.6%.
Net profit margin reached -43.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Akebia Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Akebia Therapeutics Stock Performance

Akebia Therapeutics has current market cap of $427M, and EV of $313M.

Market Cap Evolution

Akebia Therapeutics Stock Data

As of January 2, 2026, Akebia Therapeutics's stock price is $2.

See Akebia Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$313M	$427M	XXX	XXX	XXX	XXX	$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Akebia Therapeutics Valuation Multiples

Akebia Therapeutics's trades at 1.3x EV/Revenue multiple, and -22.8x EV/EBITDA.

See valuation multiples for Akebia Therapeutics and 15K+ public comps

Akebia Therapeutics Financial Valuation Multiples

As of January 2, 2026, Akebia Therapeutics has market cap of $427M and EV of $313M.

Equity research analysts estimate Akebia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Akebia Therapeutics has a P/E ratio of 34.6x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$427M	XXX	$427M	XXX	XXX	XXX
EV (current)	$313M	XXX	$313M	XXX	XXX	XXX
EV/Revenue	1.3x	XXX	1.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-22.8x	XXX	XXX	XXX
EV/EBIT	7.8x	XXX	7.8x	XXX	XXX	XXX
EV/Gross Profit	1.5x	XXX	n/a	XXX	XXX	XXX
P/E	34.6x	XXX	35.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-7.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Akebia Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Akebia Therapeutics Margins & Growth Rates

Akebia Therapeutics's last 12 month revenue growth is 22%

Akebia Therapeutics's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.

Akebia Therapeutics's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Akebia Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Akebia Therapeutics and other 15K+ public comps

Akebia Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	22%	XXX	15%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	18%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	92%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial